Tharimmune, Inc. (Nasdaq: THAR) is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors. Tharimmune has a license agreement with OmniAb, Inc. to access the company's antibody discovery technology platform against specified targets. For more information please visit: www.tharimmune.com

Biotechnology

Health Care

Life Sciences

Therapeutics

Tharimmune, Inc.

Tharimmune, Inc.'s headquarters in Bridgewater, United States

Description

People (2)

Jobs (0)

Other offices